The most well-known immunotherapeutic inhibitor based on the above immune checkpoints is the PD1 (PDCD1), and PDL1 (CD274) inhibitor, such as Pembrolizumab, has different therapeutic effects in different glioma subtypes [66–69]. This evidence concerns the gene CD274 and central nervous system cancer.